Boehringer–Peking Univ: pharma RnD, 201705– collab strategic alliance incl therapeutics + regenerative medicine + gene therapy

	Period	2017-05-16
	Partner, 1st	Boehringer Ingelheim (Group)
	Partner, 2nd	Peking University (PKU, Beijing University)
	Product	drug discovery
	Product 2	drug development

Boehringer Ingelheim. (5/16/17). "Press Release: Boehringer Ingelheim Strengthens Early Science Portfolio through Comprehensive Multifaceted Partnership with Peking University". Ingelheim & Beijing.

> Long-term collaboration to harness new scientific discoveries in areas of high unmet medical need such as cardiometabolic disease, cancer immunology and new therapeutic approaches such as regenerative medicine and gene therapy

> New partnership with one of the worldwide leading life science research institutions aims to expand portfolio of R&D projects with first in class and breakthrough potential

Boehringer Ingelheim and Peking University (PKU) today announced an ambitious strategic partnership with the aim of jointly advancing early science innovation across a range of areas of high medical need.

The partnership will implement a multifaceted collaboration model that nimbly and flexibly caters for the specific needs of the involved research groups. It will comprise project based research, a joint post-doctorate fellowship program and a number of Boehringer Ingelheim endowed investigators. The partnership aims to strengthen Boehringer Ingelheim’s portfolio of early and unique pipeline projects supporting the company’s aspiration to be at the forefront of science and technology and deliver more first in class medicines with breakthrough potential. It takes Boehringer Ingelheim’s research and development efforts in Asia to the next level.

Research teams at PKU will work closely with their counterparts at Boehringer Ingelheim to leverage the company’s expertise in pharmaceutical research and development with their novel approaches and insights to identify novel targets and medicines within and beyond the company’s key therapeutic areas. These include cancer, cancer immunology and immune modulation, respiratory, cardiometabolic and central nervous system diseases.

“We are excited to launch a comprehensive partnership program with scientists from PKU who are at the forefront of biomedical discovery. This collaboration with one of the most prestigious scientific institutions will enable us to benefit from and contribute to the impressive boom in life science research in China,” said Clive R. Wood, Ph.D., Senior Corporate Vice President, Discovery Research, Boehringer Ingelheim. “The flexible partnership model developed allows PKU and Boehringer Ingelheim scientists to work hand in hand to jointly advance promising biomedical discoveries.”

Asia, and in particular China, has gained a reputation as a leading center of excellence in biomedical research, opening new collaborative opportunities for Boehringer Ingelheim to provide the next wave of medical innovation. The PKU collaboration continues the success of recent projects in China, such as the China Southeast University Institute of Life Sciences’ project with Boehringer Ingelheim to develop new treatment approaches for hearing loss through regeneration of hair cells.

“This new collaboration with Boehringer Ingelheim reflects a mutual goal for excellence and providing innovative approaches that bridge the gap between basic science and medical development,” said Jie Wang, Vice President, Peking University, China. “We are proud to work with Boehringer Ingelheim to advance knowledge that will benefit patients in China and worldwide.”

NOTES TO THE EDITORS

About Peking University (PKU), China

Peking University (PKU) is the first national comprehensive university in China, established in 1898. It is ranked one of the top research universities in the world, consisting of 68 schools and departments with disciplines in natural sciences, humanities, social sciences, technological sciences, information science & engineering, medical sciences, etc. Currently, there are more than 20,000 faculty and staff members, over 40,000 undergraduate and graduate students, and over 347 institutes and research centers at Peking University. Some of its strong disciplines relevant to drug discovery include life sciences, chemistry, medical and pharmaceutical sciences, as well as 10 affiliated hospitals. Nowadays, Peking University has become the cradle for high-caliber and creative talents, a frontier of research and innovation, as well as a bridge for international exchanges in China. In the past few years, it has hosted the visits of the government heads of nearly 100 countries and nearly 300 chancellors of world-renown universities. It has established exchange programs with more than 384 universities from over 60 countries.

About Boehringer Ingelheim

Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.

Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Media Contact

Dr Reinhard Malin
Media Contact - Innovation Unit
Media & PR
Phone +49 6132 77 90815
Mobile +49 151 150 20690
Fax +49 6132 77 6601
› E-mail › Add Contact
Binger Strasse 173
55216 Ingelheim am Rhein
GERMANY